overview of fda's expanded access program (13/14) redi 2017
Published 4 years ago • 2.5K plays • Length 37:46Download video MP4
Download video MP3
Similar videos
-
3:41
expanded access
-
50:09
an overview of fda's project facilitate oncology expanded access program
-
46:00
introduction to investigational new drug (ind) applications (3/14) redi 2017
-
2:49
expanded access part 1: introduction
-
43:22
live demo of the fda adverse events reporting system (14/14) redi 2017
-
18:17
proposed rule: revising the national drug code format and drug label barcode requirements
-
27:57
extractables & leachables testing of single-use systems for production - karen pieters
-
4:34
expanded access part 2: how to submit a single patient ind
-
8:35
patients matter: what is expanded access?
-
37:56
regulatory and administrative components of an ind application (5/14) redi 2017
-
5:15
expanded access part 4: how to complete form fda 3926 for follow-up submissions
-
38:16
additional sponsor responsibilities (10/14) redi 2017
-
13:21
overview of the fda product-specific guidance program
-
4:40
expanded access part 3: how to complete form fda 3926 for initial submissions
-
22:18
us fda standards overview
-
6:01
fda d.i.s.c.o. burst edition: fda approvals of brukinsa (zanubrutinib), for adult patients with r...
-
24:56
api facility inspections
-
40:34
demystifying the investigational new drug (ind) application for drugs and biologics (3of14) redi '18
-
2:54
what is expanded access?
-
51:33
fda 101
-
3:31
fda d.i.s.c.o. burst edition: fda approval of imfinzi (durvalumab) for adult patients with locall...
-
3:31
fda d.i.s.c.o. burst edition: fda approval of libtayo (cemiplimab-rwlc) in combination with plati...